Merck (MRK) stock was mangled today after the pharmaceutical and vaccine company released its guidance for 2025. The company expects adjusted ...

Merck (MRK) shares drop 8% premarket as 2025 outlook falls short of Wall Street estimates, despite beating Q4 expectations ...

Reports Q4 revenue $15.6B, consensus $15.51B. “We delivered strong growth in 2024, reflecting demand for our innovative portfolio, including ...

Biopharmaceutical company Merck & Co., Inc. (MRK) reported Tuesday a net profit for the fourth quarter compared to a loss last year, ...

Merck (MRK) stock was mangled today after the ... successful launch of WINREVAIR and strong performance of our Animal Health business.” Is MRK Stock a Buy, Sell, or Hold? Turning to Wall Street, ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

the successful launch of WINREVAIR and strong performance of our Animal Health business," said Robert Davis, chairman and chief executive officer, Merck. Also Read: RJK Jr.'s Involvement In Merck ...

Rob Davis emphasized Merck's strong performance in 2024, driven by demand for KEYTRUDA, the launch of WINREVAIR, and robust growth in Animal Health. Davis highlighted challenges in GARDASIL sales in ...

Truist Securities expressed confidence in its latest note that Merck will be able to navigate the upcoming Gardasil headwinds ...

Merck said it expected sales of $64.1 billion to $65.5 billion in 2025 and adjusted earnings of $8.88 to $9.03 a share. Both forecasts came in below the average analyst expectation for revenue of ...